Regen BioPharma Inc (RGBP)

[Krisandtilly]

All eyes on RGBP Dr. Thomas Ichim, the Company's Chief Scientific Officer. "We believe that the data presented was well received by industry and academic groups, giving the company excellent exposure, and opportunities to network and collaborate with some of the world's top physicians, scientists and pharmaceutical companies."
demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome

"Acceptance of this work by the scientific committee of the American Society of Hematology (ASH) for presentation provides a strong signal
Utilizing gene silencing and small molecule inhibitors, the company is working on developing a new class of drugs that kill cancer at the level of the cancer stem cells. These are anticipated to be more effective and lack the substantial toxicity of existing chemotherapies."